Share This Page
Drug Price Trends for DM-GUAIF-PE
✉ Email this page to a colleague
Average Pharmacy Cost for DM-GUAIF-PE
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| DM-GUAIF-PE 18-200-10 MG/15 ML | 69367-0184-08 | 0.07252 | ML | 2024-09-18 |
| DM-GUAIF-PE 18-200-10 MG/15 ML | 69367-0184-08 | 0.07177 | ML | 2024-08-21 |
| DM-GUAIF-PE 18-200-10 MG/15 ML | 69367-0184-08 | 0.07177 | ML | 2024-07-17 |
| DM-GUAIF-PE 18-200-10 MG/15 ML | 69367-0184-08 | 0.07134 | ML | 2024-06-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for Guaifenesin (DM-GUAIF-PE)
Market Overview
Guaifenesin, an expectorant commonly used in medications for treating cough and chest congestion, is a significant component in the pharmaceutical industry. Here’s a comprehensive analysis of the market trends, drivers, challenges, and price projections for guaifenesin.
Market Size and Growth
The global guaifenesin market is projected to grow substantially over the next few years. By 2027, the market size is forecasted to reach USD 95 million, growing at a CAGR of around 3.1% from 2022 to 2027[1].
Geographical Trends
North America is the fastest-growing region in the global guaifenesin market, expected to grow with a CAGR of around 4.5% during the forecast period. This growth is driven by the development of medical infrastructure, increasing cases of respiratory and cough-related complications, and rising health expenditure[1].
Product Forms and Purity
Guaifenesin is available in various forms, including tablets, dissolving granules, syrup, and extended-release tablets. The market is also segmented by purity levels: below 99%, 99%, and above 99%. The demand for guaifenesin across these segments is increasing due to its widespread use in pharmaceutical medications and cough treatment drugs[1].
Drivers of the Market
Increasing Number of Cough Cases
The rise in whooping cough (pertussis) cases and other respiratory complications is a significant driver for the guaifenesin market. According to the CDC, there are approximately 24.1 million pertussis cases and 16,700 deaths worldwide each year, which boosts the demand for guaifenesin-based medications[1].
Growing Demand in the Hospital Sector
Guaifenesin has a growing demand in hospitals for treating cough, chest congestion, and other respiratory issues. The advancement in drug technology and the growth in the pharmaceutical sector further fuel this demand. The hospital sector in India, for example, is expected to rise significantly, contributing to the global demand for guaifenesin[1].
Impact of COVID-19
The COVID-19 pandemic had a significant impact on the global guaifenesin market. Initially, the pandemic caused disruptions in production, supply chains, and hospital infrastructure. However, the surging demand for cough and cold medications during the recovery phase led to major growth opportunities. Medicaid spending increased by 9.2% to USD 671.2 billion in 2020, and hospital spending in the US saw a 6.4% increase, indicating a robust healthcare sector post-pandemic[1].
Challenges and Restraints
Availability of Substitutes and Potential Side Effects
One of the major challenges facing the guaifenesin market is the availability of substitutes. Additionally, potential side effects associated with guaifenesin can deter some consumers, although it remains a widely used and effective expectorant[1].
Price Projections and Cost Analysis
The cost of guaifenesin-based medications varies depending on the form and dosage. For instance, the oral liquid form of dextromethorphan/guaifenesin can cost around $12 for a 473 milliliter supply, while extended-release tablets can range from $10.72 to $28.19 for different quantities[2].
Price Trends
- Oral Liquid: $12.33 for 473 milliliters
- Extended-Release Tablets: $28.19 for 28 tablets (60 mg-1200 mg)[2].
Discounts and Patient Assistance
Patients can benefit from discount cards and copay programs, which can reduce the cost of guaifenesin-based medications by up to 80% or more. These programs are available at most major pharmacies and can significantly lower the out-of-pocket costs for consumers[2].
Key Market Trends
- Regulatory Approvals: The FDA approval for new guaifenesin-based drugs, such as Mucinex DM Maximum Strength, has driven market growth. These approvals indicate a favorable regulatory environment for guaifenesin products[4].
- Restrictions on Codeine: Strict regulations against the use of codeine in many countries have created opportunities for non-opioid expectorants like guaifenesin, boosting its market growth[4].
Regional Demand and Supply
The demand for guaifenesin is particularly high in regions with developing medical infrastructure and increasing cases of respiratory diseases. North America, with its large pharmaceutical market, accounts for the largest share of guaifenesin sales, with 49% of global pharmaceutical sales in 2020[1].
Future Outlook
The future of the guaifenesin market looks promising, driven by increasing demand for cough and cold medications, advancements in pharmaceutical technology, and the recovery of the healthcare sector post-COVID-19. The market is expected to continue growing as more countries invest in healthcare infrastructure and as the awareness of guaifenesin's benefits increases.
"The guaifenesin market will experience major growth and demand in the coming years, driven by the flourishing hospital infrastructure, growth in drug production, and healthcare development post-COVID-19 phase"[1].
Key Takeaways
- The global guaifenesin market is projected to reach USD 95 million by 2027.
- North America is the fastest-growing region due to its developing medical infrastructure and rising health expenditure.
- The COVID-19 pandemic initially disrupted the market but later led to increased demand for cough and cold medications.
- The availability of substitutes and potential side effects are significant challenges.
- Regulatory approvals and restrictions on codeine use are driving factors for the market.
- The cost of guaifenesin-based medications can be reduced through discount cards and copay programs.
Frequently Asked Questions (FAQs)
1. What is the projected market size of guaifenesin by 2027?
The global guaifenesin market is forecasted to reach USD 95 million by 2027[1].
2. Which region is the fastest-growing in the guaifenesin market?
North America is the fastest-growing region in the global guaifenesin market, expected to grow with a CAGR of around 4.5% during the forecast period[1].
3. How did the COVID-19 pandemic impact the guaifenesin market?
The COVID-19 pandemic initially caused disruptions in production and supply chains but later led to increased demand for cough and cold medications, driving market growth[1].
4. What are the main challenges facing the guaifenesin market?
The main challenges include the availability of substitutes and potential side effects associated with guaifenesin[1].
5. How can patients reduce the cost of guaifenesin-based medications?
Patients can use discount cards and copay programs, which can reduce the cost of guaifenesin-based medications by up to 80% or more[2].
Sources:
- IndustryARC, "Guaifenesin Market Size Report, 2022-2027".
- Drugs.com, "Dextromethorphan/guaifenesin Prices, Coupons, Copay Cards & Patient Assistance".
- GlobeNewswire, "Global Psychedelic Drugs Market Size To Worth USD 8.7 Billion By 2033".
- Allied Market Research, "Guaifenesin Market Size, Trends | Industry Report 2021 - 2030".
- UCare, "2025 UCare Medicare Group Formulary - UCare Core".
More… ↓
